Archive for the Home Page Category

Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa

Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa

Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa

Productive FDA meeting paves the way for BLA submission for MCO-010 in Q1 2025

Nanoscope Therapeutics Licenses Optogenetic CatCh Technology

Nanoscope Therapeutics Licenses Optogenetic CatCh Technology

Nanoscope Therapeutics Licenses Optogenetic CatCh Technology

Innovative technology incorporated in Nanoscope’s gene therapy offers hope for restoring vision in genetically caused visual impairments

Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona

Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona

Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona

Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration

–Phase 3 Registrational Trial Expected to Commence in Near-term

Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon

Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon

Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon

Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect

Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect

Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect

Nanoscope Therapeutics to Present at the BIO International Convention

Nanoscope Therapeutics to Present at the BIO International Convention

Nanoscope Therapeutics to Present at the BIO International Convention

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

  • MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events
  • Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina
  • RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease
  • Nanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.